EGFR and non-small cell lung carcinoma: Even though all of the genetic alterations, especially anaplastic lymphoma kinase (ALK) fusion oncogene mutation and alteration in epidermal growth factor receptor (EGFR) in NSCLC, are well understood, certain limitations still need to be addressed (8–10).